Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint

Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint Corcept Therapeutics Incorporated (NASDAQ: CORT), a company focused on developing treatments for serious endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced that its pivotal…